Today: 25 January 2026
Subscribe
Browse Category

NASDAQ:LQDA News 9 January 2026 - 11 January 2026

Liquidia stock jumps after $148.3 million YUTREPIA sales update — what LQDA investors watch next week

Liquidia stock jumps after $148.3 million YUTREPIA sales update — what LQDA investors watch next week

New York, Jan 11, 2026, 08:01 EST — Market closed. Shares of Liquidia Corporation jumped 12.9% to close at $35.86 on Friday, following a strong sales surge for its inhaled treprostinil therapy, YUTREPIA. The stock traded between $29.41 and $38.07 throughout the day. This shift carries weight as Liquidia remains in the early phase of its commercial rollout. Investors want…
11 January 2026
·····
Liquidia stock jumps after $148 mln Yutrepia sales update — what to watch next week

Liquidia stock jumps after $148 mln Yutrepia sales update — what to watch next week

New York, Jan 10, 2026, 19:48 EST — Market closed Shares of Liquidia Corp surged 12.9% on Friday, closing at $35.86 following a preliminary sales update on its pulmonary hypertension drug YUTREPIA. The company also reported positive cash flow in Q4. During the session, the stock hit a high of $38.07 and was trading about 1.5% higher in after-hours, per…
11 January 2026
·····
Liquidia stock jumps 13% after $148M Yutrepia sales update; what investors watch next

Liquidia stock jumps 13% after $148M Yutrepia sales update; what investors watch next

New York, Jan 10, 2026, 09:08 ET — Market closed Key points: Liquidia Corporation shares climbed 12.9% on Friday to $35.86, extending a sharp run after the drugmaker laid out preliminary 2025 sales for its inhaled pulmonary hypertension drug, Yutrepia. The update matters because Yutrepia is now the engine of the story, not a promise. It is also a test…
10 January 2026
·····
Liquidia stock jumps nearly 15% after Yutrepia sales update, cash-flow claim

Liquidia stock jumps nearly 15% after Yutrepia sales update, cash-flow claim

New York, Jan 9, 2026, 11:53 EST — Regular session Liquidia Corp shares jumped nearly 15% in morning trading on Friday after the drugmaker posted preliminary full-year figures for its newly launched pulmonary drug, easing near-term worries about demand and cash use. The move matters because Yutrepia is Liquidia’s main growth engine, and the stock has been trading like a…
9 January 2026
·····

Stock Market Today

  • Planet Labs (PL) Shares Surge Amid Overvaluation Concerns
    January 24, 2026, 11:40 PM EST. Planet Labs PBC (PL) has seen its share price surge 39.2% over 30 days, with a remarkable 395.2% gain over one year. Despite this strong performance, valuation metrics suggest caution. Simply Wall St's discounted cash flow (DCF) analysis estimates an intrinsic value of $2.11 per share, while the current price is over ten times that figure, indicating a potential overvaluation of 1179.1%. The stock has experienced volatility, including a recent 6.4% drop in the past week, reflecting mixed investor sentiment around its satellite-based Earth imaging business. Simply Wall St assigns a value score of 0 out of 6, highlighting red flags for prospective investors. These valuation concerns underline the importance of thorough analysis even amid impressive stock rallies.
Go toTop